Table A3.
Number of individuals in Victoria dispensed antiretroviral treatment (ART) through the Highly Specialised Drugs Program by year and antiretroviral agent
| Year ARV drugs dispensed1 | |||||||
|---|---|---|---|---|---|---|---|
| 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | |
| NRTIs | |||||||
| Abacavir | 198 | 316 | 273 | 304 | 331 | 344 | 181 |
| Didanosine | 291 | 288 | 289 | 231 | 259 | 194 | 142 |
| Emtricitabine | n/a | n/a | n/a | n/a | n/a | 37 | 19 |
| Lamivudine2 | 681 | 623 | 563 | 592 | 694 | 734 | 442 |
| Stavudine | 764 | 629 | 471 | 336 | 265 | 156 | 99 |
| Tenofovir | n/a | n/a | 210 | 392 | 480 | 668 | 609 |
| Zalcitabine | 35 | 28 | 17 | 8 | 6 | 5 | 2 |
| Zidovudine | 220 | 301 | 84 | 72 | 66 | 57 | 51 |
| Lamivudine & Zidovudine | 367 | 451 | 482 | 536 | 558 | 548 | 436 |
| Abacavir & Lamivudine | n/a | n/a | n/a | n/a | n/a | n/a | 456 |
| Abacavir & Lamivudine & Zidovudine | n/a | 37 | 176 | 229 | 199 | 164 | 129 |
| Tenofovir & Emtricitabine | n/a | n/a | n/a | n/a | n/a | n/a | 339 |
| NNRTIs | |||||||
| Delavirdine | 4 | 11 | 10 | 11 | 13 | 9 | 10 |
| Efavirenz | 235 | 243 | 217 | 250 | 297 | 363 | 489 |
| Nevirapine | 583 | 616 | 603 | 655 | 706 | 1,025 | 735 |
| PIs | |||||||
| Amprenavir | n/a | n/a | 37 | 43 | 30 | 8 | 3 |
| Atazanavir | n/a | n/a | n/a | n/a | 110 | 253 | 407 |
| Indinavir | 259 | 226 | 164 | 106 | 86 | 51 | 36 |
| Fosamprenavir | n/a | n/a | n/a | n/a | 2 | 37 | 56 |
| Kaletra (Lopinavir & ritonavir) | n/a | n/a | 184 | 271 | 330 | 330 | 329 |
| Nelfinavir | 196 | 165 | 119 | 98 | 82 | 56 | 33 |
| Ritonavir | 168 | 174 | 134 | 122 | 158 | 254 | 392 |
| Saquinavir | 173 | 143 | 91 | 66 | 53 | 39 | 37 |
| FI | |||||||
| Enfuvirtide | n/a | n/a | n/a | n/a | 19 | 47 | 53 |
We have estimated the number of people dispensed each antiretroviral drug during a calendar year period by calculating the average of the total number of patients dispensed each drug during the corresponding finanical year quarters
The number of patients on lamivudine per calendar year is estimated by deducting the number of patient years of lamivudine for HBV treatment (calculated from the national pack numbers report) from the total number of patients dispensed lamivudine for the purpose of HIV & HBV treatment; n/a indicates that the data or the ARV drug were not available.
FI, fusion inhibitors; NNRTI, non-nucleoside reverse transcriptase inhibitors; NRTI, nucleoside reverse transcriptase inhibitors; PI, protease inhibitors.
Source: Australian Government Highly Specialised Drugs (S100) Program.